Use of anti-CD40 ligand monoclonal antibody as antirejection therapy in a murine peripheral nerve allograft model

Microsurgery

Volumn 24, Issue 4, 2004, Pages 309-315

  Jensen, John N ^a   Tung, Thomas H H ^a   Mackinnon, Susan E ^a   Brenner, Michael J ^a   Hunter, Daniel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPAMEZOLE; CD40 LIGAND MONOCLONAL ANTIBODY;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG USE; GRAFT REJECTION; ISOGRAFT; MALE; MOUSE; NERVE GRAFT; NONHUMAN; ORGAN TRANSPLANTATION; PERIPHERAL NERVE; PRIORITY JOURNAL; REGENERATION; SCIATIC NERVE; TIBIAL NERVE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; GRAFT REJECTION; IMMUNOSUPPRESSION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MODELS, ANIMAL; PERIPHERAL NERVES; RECOVERY OF FUNCTION; TISSUE TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 3343003554     PISSN: 07381085     EISSN: None     Source Type: Journal    
DOI: 10.1002/micr.20028     Document Type: Article

References (24)

1. Bain JR, Mackinnon SE, Hudson AR, Falk RE, Falk JA, Hunter DA. The peripheral nerve allograft: a dose-response curve in the rat immunosuppressed with cyclosporin A. Plast Reconstr Surg 1988;82:447-457.
2. Midha R, Evans PJ, Mackinnon SE, Wade JA. Temporary immunosuppression for peripheral nerve allografts. Transplant Proc 1993;25:532-536.
3. Midha R, Mackinnon SE, Evans PJ, Best TJ, Hare GM, Hunter DA, Falk-Wade JA. Comparison of regeneration across nerve allografts with temporary or continuous cyclosporin A immunosuppression. J Neurosurg 1993;78:90-100.
4. Midha R, Mackinnon SE, Becker LE. The fate of Schwann cells in peripheral nerve allografts. J Neuropathol Exp Neurol 1994;53: 316-322.
5. Illei GG, Klippel JH. Novel approaches in the treatment of lupus nephritis. Lupus 1998;79:644-648.
6. Renshaw BR, Fanslow WC III, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994;180:1889-1900.
7. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378: 617-620.
8. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997;9: 641-647.
9. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendrix R, Pearson TC. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996;61:4-9.
10. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
11. Elwood ET, Larsen CP, Cho HR, Corbascio M, Ritchie SC, Alexander DZ, Tucker-Buren C, Linsley PS, Aruffo A, Hollenbaugh D, Winn KJ, Pearson TC. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998;65:1422-1428.
12. Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Menoret S, Braudeau C, Tesson L, Renaudin K, Castro MG, Lowenstein PR, Anegon I. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002;168:1600-1609.
13. Kirk AD. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit Rev Immunol 1999;19:349-388.
14. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4: Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Pro Nat Acad Sci USA 1997;94:8789-8794.
15. Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD 154 in nonhuman primate renal transplantation. Transplantation 2002;74:1365-3169.
16. Xu H, Tadaki DK, Elster EA, Burkly LC, Berning JD, Cruzata F, Kampen RL, Montgomery SP, Patterson NB, Harlan DM, Kirk AD. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002;74:940-943.
17. Cho CS, Brukly LC, Fechner JH Jr, Kirk AD, Oberley TD, Dong Y, Brunner KG, Peters D, Tenhoor CN, Nadeau K, Yagci G, Ishido N, Schultz JM, Tsuchida M. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 2001;72:587-597.
18. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, Laria G, Han D, Wagner JL, Rulz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999;48:1473-1481.
19. Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM. Central role for CD40/CD40 ligand (CD 154) interactions in transplant rejection. Pediatr Transplant 1998;2: 6-15.
20. Inserra MM, Bloch DA, Terris DJ. Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse. Microsurgery 1998;18:119-124.
21. Yao M, Inserra MM, Duh MJ, Terris DJ. A longitudinal, functional study of peripheral nerve recovery in the mouse. Laryngoscope 1998;108:1141-1145.
22. Hare GM, Evans PJ, Mackinnon SE, Best TJ, Midha R, Szalai JP, Tesson L, Renaudin K, Castro MG, Lowenstein PR, Anegon I. Walking track analysis: utilization of individual footprint parameters. Ann Plast Surg 1993;30:147-153.
23. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, Techoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD 154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686-693.
24. Mackinnon SE, Doolabh VB, Novak CB, Trulock EP. Clinical outcome following nerve allograft transplantation. Plast Reconstr Surg 2001;107:1419-1429.